Hanmi Pharm in spotlight as Korea's 1st obesity drug nears launch
Hanmi Pharmaceutical is gaining attention as it prepares to launch Korea’s first glucagon-like peptide-1 (GLP-1)-based obesity drug, Eppe, while also signing a licensing deal worth up to $2.3 billion for a separate obesity drug candidate. Analysts at domestic brokerages have raised their price target on Hanmi Pharm, citing the company’s potential in obesity drugs.
Brief written by urgent.news from The Korea Times's own syndicated text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- Hanmi Pharm in spotlight as Korea's 1st obesity drug nears launch koreatimes.co.kr
